Clearance of Intracranial Blood Products by Continuous Irrigation With the IRRAflow System
Recruiting · NCT06649097
Conditions: Intracranial Hemorrhage, Ventriculitis, Intracranial Abscess
At a glance
- Research payments reported, 2025
- $775,000
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 250
About the trial
- Sponsor
- Christopher P Kellner (with IRRAS)
- Tested
- IRRAflow® CNS (Active Fluid Exchange) System (device)
- Dates
- Started 2025-09-25; completion 2031-07
- Results posted
- Not yet
The study is a multi-center prospective cohort, controlled, phase 4 post-market registry evaluating the efficacy and radiographic outcomes associated with the use of the IRRAflow® Active Fluid Exchange System compared to standard of care external ventricular drains.
From ClinicalTrials.gov, last updated 2025-10-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Irras USA, Inc. reported $775,000 in research payments for this study in 2025 (3 payments).
Products named: Irraflow
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.